Photosensitivity Reaction From Dronedarone for Atrial Fibrillation

Article Type
Changed
Thu, 01/10/2019 - 13:18
Display Headline
Photosensitivity Reaction From Dronedarone for Atrial Fibrillation

To the Editor:
A 61-year-old woman with a history of atrial fibrillation, type 2 diabetes mellitus, and hyperlipidemia presented with an erythematous, edematous, pruritic eruption on the chest, neck, and arms of 2 weeks’ duration. The patient had no history of considerable sun exposure or reports of photosensitivity. One month prior to presentation she had started taking dronedarone for improved control of atrial fibrillation. She had no known history of drug allergies. Other medications included valsartan, digoxin, pioglitazone, simvastatin, aspirin, hydrocodone, and zolpidem, all of which were unchanged for years. There were no changes in topical products used.

Physical examination revealed confluent, well-demarcated, erythematous and edematous papules and plaques over the anterior aspect of the neck, bilateral forearms, and dorsal aspect of the hands, with a v-shaped distribution on the chest (Figure). There was notable sparing of the submental region, upper arms, abdomen, back, and legs. Dronedarone was discontinued and she was started on fluocinonide ointment 0.05% and oral hydroxyzine for pruritus. Her rash resolved within the following few weeks.

Confluent, well-demarcated, erythematous and edematous papules and plaques in a v-shaped distribution on the chest (A) and dorsal aspect of the hands (B).

Dronedarone is a noniodinated benzofuran derivative. It is structurally similar to and shares the antiarrhythmic properties of amiodarone,1 and thus it is used in the treatment of atrial fibrillation and atrial flutter. However, the pulmonary and thyroid toxicities sometimes associated with amiodarone have not been observed with dronedarone. The primary side effect of dronedarone is gastrointestinal distress, specifically nausea, vomiting, and diarrhea. Dronedarone has been associated with severe liver injury and hepatic failure.2 Cutaneous reactions appear to be an uncommon side effect of dronedarone therapy. Across 5 clinical studies (N=6285), adverse events involving skin and subcutaneous tissue including eczema, allergic dermatitis, pruritus, and nonspecific rash occurred in 5% of dronedarone and 3% of placebo patients. Photosensitivity reactions occurred in less than 1% of dronedarone recipients.3

Although the lack of a biopsy leaves the possibility of a contact or photocontact dermatitis, our patient demonstrated the potential for dronedarone to cause a photodistributed drug eruption that resolved after cessation of the medication.

References

1. Hoy SM, Keam  SJ. Dronedarone. Drugs. 2009;69:1647-1663.

2. In brief: FDA warning on dronedarone (Multaq). Med Lett Drugs Ther. 2011;53:17.

3. Multaq [package insert]. Bridgewater, NJ: sanofi-aventis; 2009.

Article PDF
Author and Disclosure Information

Sandy Kuo, MD; Kavita Menon, MD; Roopal V. Kundu, MD

Dr. Kuo is from Chicago Medical School, Rosalind Franklin University of Medicine, Illinois. Drs. Menon and Kundu are from the Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago.

The authors report no conflict of interest.

Correspondence: Roopal V. Kundu, MD, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Ste 1600, Chicago, IL 60611 (rkundu@nmff.org).

Issue
Cutis - 94(5)
Publications
Topics
Page Number
E10-E11
Legacy Keywords
photosensitivity, rash, dronedarone, case report, drug reaction
Sections
Author and Disclosure Information

Sandy Kuo, MD; Kavita Menon, MD; Roopal V. Kundu, MD

Dr. Kuo is from Chicago Medical School, Rosalind Franklin University of Medicine, Illinois. Drs. Menon and Kundu are from the Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago.

The authors report no conflict of interest.

Correspondence: Roopal V. Kundu, MD, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Ste 1600, Chicago, IL 60611 (rkundu@nmff.org).

Author and Disclosure Information

Sandy Kuo, MD; Kavita Menon, MD; Roopal V. Kundu, MD

Dr. Kuo is from Chicago Medical School, Rosalind Franklin University of Medicine, Illinois. Drs. Menon and Kundu are from the Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago.

The authors report no conflict of interest.

Correspondence: Roopal V. Kundu, MD, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Ste 1600, Chicago, IL 60611 (rkundu@nmff.org).

Article PDF
Article PDF
Related Articles

To the Editor:
A 61-year-old woman with a history of atrial fibrillation, type 2 diabetes mellitus, and hyperlipidemia presented with an erythematous, edematous, pruritic eruption on the chest, neck, and arms of 2 weeks’ duration. The patient had no history of considerable sun exposure or reports of photosensitivity. One month prior to presentation she had started taking dronedarone for improved control of atrial fibrillation. She had no known history of drug allergies. Other medications included valsartan, digoxin, pioglitazone, simvastatin, aspirin, hydrocodone, and zolpidem, all of which were unchanged for years. There were no changes in topical products used.

Physical examination revealed confluent, well-demarcated, erythematous and edematous papules and plaques over the anterior aspect of the neck, bilateral forearms, and dorsal aspect of the hands, with a v-shaped distribution on the chest (Figure). There was notable sparing of the submental region, upper arms, abdomen, back, and legs. Dronedarone was discontinued and she was started on fluocinonide ointment 0.05% and oral hydroxyzine for pruritus. Her rash resolved within the following few weeks.

Confluent, well-demarcated, erythematous and edematous papules and plaques in a v-shaped distribution on the chest (A) and dorsal aspect of the hands (B).

Dronedarone is a noniodinated benzofuran derivative. It is structurally similar to and shares the antiarrhythmic properties of amiodarone,1 and thus it is used in the treatment of atrial fibrillation and atrial flutter. However, the pulmonary and thyroid toxicities sometimes associated with amiodarone have not been observed with dronedarone. The primary side effect of dronedarone is gastrointestinal distress, specifically nausea, vomiting, and diarrhea. Dronedarone has been associated with severe liver injury and hepatic failure.2 Cutaneous reactions appear to be an uncommon side effect of dronedarone therapy. Across 5 clinical studies (N=6285), adverse events involving skin and subcutaneous tissue including eczema, allergic dermatitis, pruritus, and nonspecific rash occurred in 5% of dronedarone and 3% of placebo patients. Photosensitivity reactions occurred in less than 1% of dronedarone recipients.3

Although the lack of a biopsy leaves the possibility of a contact or photocontact dermatitis, our patient demonstrated the potential for dronedarone to cause a photodistributed drug eruption that resolved after cessation of the medication.

To the Editor:
A 61-year-old woman with a history of atrial fibrillation, type 2 diabetes mellitus, and hyperlipidemia presented with an erythematous, edematous, pruritic eruption on the chest, neck, and arms of 2 weeks’ duration. The patient had no history of considerable sun exposure or reports of photosensitivity. One month prior to presentation she had started taking dronedarone for improved control of atrial fibrillation. She had no known history of drug allergies. Other medications included valsartan, digoxin, pioglitazone, simvastatin, aspirin, hydrocodone, and zolpidem, all of which were unchanged for years. There were no changes in topical products used.

Physical examination revealed confluent, well-demarcated, erythematous and edematous papules and plaques over the anterior aspect of the neck, bilateral forearms, and dorsal aspect of the hands, with a v-shaped distribution on the chest (Figure). There was notable sparing of the submental region, upper arms, abdomen, back, and legs. Dronedarone was discontinued and she was started on fluocinonide ointment 0.05% and oral hydroxyzine for pruritus. Her rash resolved within the following few weeks.

Confluent, well-demarcated, erythematous and edematous papules and plaques in a v-shaped distribution on the chest (A) and dorsal aspect of the hands (B).

Dronedarone is a noniodinated benzofuran derivative. It is structurally similar to and shares the antiarrhythmic properties of amiodarone,1 and thus it is used in the treatment of atrial fibrillation and atrial flutter. However, the pulmonary and thyroid toxicities sometimes associated with amiodarone have not been observed with dronedarone. The primary side effect of dronedarone is gastrointestinal distress, specifically nausea, vomiting, and diarrhea. Dronedarone has been associated with severe liver injury and hepatic failure.2 Cutaneous reactions appear to be an uncommon side effect of dronedarone therapy. Across 5 clinical studies (N=6285), adverse events involving skin and subcutaneous tissue including eczema, allergic dermatitis, pruritus, and nonspecific rash occurred in 5% of dronedarone and 3% of placebo patients. Photosensitivity reactions occurred in less than 1% of dronedarone recipients.3

Although the lack of a biopsy leaves the possibility of a contact or photocontact dermatitis, our patient demonstrated the potential for dronedarone to cause a photodistributed drug eruption that resolved after cessation of the medication.

References

1. Hoy SM, Keam  SJ. Dronedarone. Drugs. 2009;69:1647-1663.

2. In brief: FDA warning on dronedarone (Multaq). Med Lett Drugs Ther. 2011;53:17.

3. Multaq [package insert]. Bridgewater, NJ: sanofi-aventis; 2009.

References

1. Hoy SM, Keam  SJ. Dronedarone. Drugs. 2009;69:1647-1663.

2. In brief: FDA warning on dronedarone (Multaq). Med Lett Drugs Ther. 2011;53:17.

3. Multaq [package insert]. Bridgewater, NJ: sanofi-aventis; 2009.

Issue
Cutis - 94(5)
Issue
Cutis - 94(5)
Page Number
E10-E11
Page Number
E10-E11
Publications
Publications
Topics
Article Type
Display Headline
Photosensitivity Reaction From Dronedarone for Atrial Fibrillation
Display Headline
Photosensitivity Reaction From Dronedarone for Atrial Fibrillation
Legacy Keywords
photosensitivity, rash, dronedarone, case report, drug reaction
Legacy Keywords
photosensitivity, rash, dronedarone, case report, drug reaction
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media